Sanaria

Sanaria is a biotechnology company developing vaccines protective against malaria, as well as related products for use in malaria research.^[1] Sanaria’s vaccines are based on the use of the sporozoite stage of the Plasmodium parasite as immunogen. Sanaria has developed the technology to grow and harvest large quantities of aseptic, purified Plasmodium sporozoites and formulate them for use in vaccines for human use. Sanaria's initial candidate vaccine is called Sanaria PfSPZ, and uses radiation attenuated Plasmodium falciparum sporozoites as immunogen. Sanaria is developing other vaccines, including Sanaria PfSPZ-CVac, which uses unattenuated sporozoites in the presence of antimalarial drugs as immunogen; genetically attenuated sporozoites as immunogen, and other species of Plasmodium in all these formulations.^[2]

Mission Statement

Sanaria's mission is to create malaria vaccines using whole-parasite sporozoites to protect against Plasmodium falciparum.^[3]

History

Headquartered in Rockville, Maryland, Dr. Stephen Hoffman founded Sanaria Inc. in 2003. From 1987–2000 Hoffman was director of the U.S. Navy’s Malaria Research and Development Program. From 2000–2002 he was Senior VP Biologics at Celera Genomics. He is past president of American Society of Tropical Medicine and Hygiene, a member of the National Academy of Medicine (formerly the Institute of Medicine), the most highly cited author in the world for scientific papers published on malaria from 1995 to 2005, author of more than 400 scientific publications, and holds numerous patents worldwide.^[4]

Awards

• 2015 Montgomery County Bioscience Company of the Year at the 3rd Annual Montgomery County Small Business Awards^[5]
• 2014 Best Prophylactic Vaccine – World Vaccine Congress, Vaccine Industry Excellence Awards^[6]
• 2013 Emerging Business of the Year – Montgomery County Chamber of Commerce^[7]
• 2012 Commercialization Award – Maryland Biotech Center^[8]
• 2011 Biotechnology Firm of the Year – Tech Council of Maryland^[9]
• 2010 Innovator of the Year – The Daily Record^[10]
• 2010 Ranked 15th in The Gazette of Politics and Business Exceptional 53 Business Award^[11]
• 2009 Best Early-Stage Vaccine Biotech – Vaccine Congress Washington, Vaccine Industry Excellence Awards^[12]
• 2009 Ranked 22nd in The Gazette of Politics and Business Exceptional 53 Business Award^[13]
• 2008 Emerging Company of the Year – Tech Council of Maryland Tech Awards^[14]

References

External links

Company website